Advances in the study of antisense long‐stranded non‐coding RNAs in tumors (Review)
Yifan Shao,Yuwei Dong,Jing Zhou,Zhihua Lu,Chen Chen,Xiaomin Yuan,Linhai He,Wenwen Tang,Zepeng Chen,Yuji Wang,Qiurong Li,Shuhui Zhan,Zhengxi Qiu,Kuiling Wang,Jiaze Ma,Yugen Chen,Yang Li
DOI: https://doi.org/10.3892/ijo.2024.5610
2024-01-09
International Journal of Oncology
Abstract:Long‑stranded non‑coding RNAs (lncRNAs) are RNAs that consist of >200 nucleotides. The majority of lncRNAs do not encode proteins but have been revealed to mediate a variety of important physiological functions. Antisense‑lncRNAs (AS‑lncRNAs) are transcribed from the opposite strand of a protein or non‑protein coding gene as part of the antisense strand of the coding gene. AS‑lncRNAs can serve an important role in the tumorigenesis, prognosis, metastasis and drug resistance of a number of malignancies. This has been reported to be exerted through various mechanisms, such as endogenous competition, promoter interactions, direct interactions with mRNAs, acting as 'scaffolds' to regulate mRNA half‑life, interactions with 5‑untranslated regions and regulation of sense mRNAs. AS‑lncRNAs have been found to either inhibit or promote tumor aggressiveness by regulating cell proliferation, energy metabolism, inflammation, inflammatory‑carcinoma transformation, invasion, migration and angiogenesis. In addition, accumulating evidence has documented that AS‑lncRNAs can regulate tumor therapy resistance. Therefore, targeting aberrantly expressed AS‑lncRNAs for cancer treatment may prove to be a promising approach to reverse therapy resistance. In the present review, research advances on the role of AS‑lncRNAs in tumor occurrence and development were summarized, with the aim of providing novel ideas for further research in this field.
oncology